Core Viewpoint - Rebio Biotech-B (06938) is recognized as a leader in the small RNA field in China, with significant market potential and a robust pipeline of drug candidates [1] Company Overview - Rebio Biotech has a fully integrated technology platform, particularly in delivery technology, and is often referred to as the "Chinese version of Alnylam" [1] - The company has six self-developed siRNA drugs currently in clinical trials, targeting seven indications, with four of them in Phase 2 trials [1] - Over 20 preclinical assets are also in development [1] Market Potential - By 2026, approximately 26.7 million people globally will be affected by thrombotic diseases, with the anticoagulant drug market projected to reach around $70 billion [1] - The company's pipeline targets FXI, effectively mitigating bleeding risks associated with existing drugs, and siRNA offers long-lasting and safe treatment options [1] Competitive Landscape - The company's pipeline has first-in-class (FIC) potential and has already entered Phase 2 clinical trials, specifically in a Phase 2a trial for coronary artery disease [1] - The company plans to initiate Phase 2b clinical trials within the year [1] - Phase 1 clinical data indicates that the company's product demonstrates superior anticoagulant effects with strong safety profiles, showing no serious adverse events related to the drug [1] - The peak potential of the product is estimated to reach a scale of $10 billion [1]

Core Insights - The J.P. Morgan Healthcare Conference highlighted WuXi Biologics' strategic growth in the biopharmaceutical sector, with a focus on expanding its project pipeline and capabilities in complex biologics, particularly bispecific antibodies [1][2] Group 1: Business Growth and Project Pipeline - WuXi Biologics plans to add 209 new integrated projects by 2025, bringing the total to 945 projects, with bispecific antibodies and ADCs becoming key growth drivers [1][2] - The company anticipates continued business growth momentum into 2026, with approximately half of the new projects originating from the U.S. market [1][9] - The bispecific antibody market is projected to grow significantly, with a compound annual growth rate (CAGR) of 32.4% from 2024 to 2034, reaching a market size of $221.8 billion by 2034 [2] Group 2: Technological Advancements - WuXi Biologics has developed proprietary platforms such as WuXiBody™ for bispecific antibodies, which have led to a robust project pipeline with nearly 20 projects in the R&D phase [3] - The company has introduced key development platforms, including WuXia™ TrueSite and WuXiHigh™2.0, aimed at enhancing production efficiency and stability in biologics [6][7] - The introduction of the digital twin platform PatroLab™ allows for real-time monitoring of critical process parameters, significantly improving data density and operational insights [12] Group 3: Global Expansion Strategy - WuXi Biologics is expanding its global footprint, with strategic investments in the U.S. and the establishment of a new CRDMO center in Qatar, marking its sixth global hub [1][10][11] - The company aims to replicate its successful production processes and management systems globally, enhancing its operational resilience and capacity to meet diverse client needs [11] - By 2029, WuXi Biologics expects to have over 370,000 liters of large-scale production capacity, with an annual output of 30 tons of biopharmaceuticals [11]

Group 1 - The core point of the news is that Nanmo Biotechnology experienced a decline of 5.82% in its stock price, reaching 51.80 yuan per share, with a trading volume of 30.42 million yuan and a turnover rate of 0.74%, resulting in a total market capitalization of 4.039 billion yuan [1] - Nanmo Biotechnology, established on September 20, 2000, and listed on December 28, 2021, specializes in the research, production, sales, and related technical services of genetically modified animal models [1] - The revenue composition of Nanmo Biotechnology includes standardized models (48.34%), model technical services (21.92%), model breeding (19.50%), customized models (9.34%), and other supplementary services (0.91%) [1] Group 2 - Tianhong Fund's Tianhong Medical Health A (001558) has entered the top ten circulating shareholders of Nanmo Biotechnology, holding 377,400 shares, which accounts for 0.48% of the circulating shares, with an estimated floating loss of approximately 1.2078 million yuan [2] - Tianhong Medical Health A was established on June 30, 2015, with a latest scale of 263 million yuan, achieving a year-to-date return of 16.59% and a one-year return of 56.11% [2] - The fund manager of Tianhong Medical Health A is Lü Qiao, who has a total fund asset scale of 506 million yuan, with the best fund return during the tenure being 48.08% and the worst being 47.47% [3]

Liquidia Conference Call Summary Company Overview - **Company**: Liquidia - **Industry**: Biopharmaceuticals, specifically focused on inhaled drug delivery for pulmonary diseases - **Key Product**: Yutrepia, FDA approved on May 23, 2025, for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3][5] Financial Performance - **2025 Performance**: Achieved profitability in the first quarter post-launch with net product sales of $148.3 million, growing from $51.7 million in Q3 2025 to $90.1 million in Q4 2025, representing a 75% quarter-over-quarter growth [5][6] - **Cash Flow**: Generated over $30 million in positive cash flow, strengthening the balance sheet [6][31] Market Opportunity - **Market Size**: The prostacyclin market for PAH and PH-ILD is estimated at $4.3 billion annually, with inhaled therapies generating $1.7 billion, oral therapies nearly $2 billion, and parenteral therapies about $572 million [6][7] - **Patient Population**: Approximately 18,000 patients for PAH, 60,000 for PHALD, 30,000 for scleroderma, 200,000 for idiopathic pulmonary fibrosis (IPF), and 300,000 for pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) [24] Product Development and Pipeline - **Yutrepia Launch**: Launched in June 2025, with 2,800 new prescriptions and a conversion rate from referral to start of 85% [8][9] - **Clinical Studies**: Ongoing studies include the ASCENT study for PH-ILD, transitioning patients from Tyvaso to Yutrepia, and a study for transitioning patients from oral therapies [14][15][16] - **L606 Development**: An extended-release liposomal formulation expected to provide more consistent exposure and potentially better tolerability compared to existing therapies [25][27] Competitive Landscape - **Market Share**: Liquidia has captured approximately 25% market share in the inhaled treprostinil space within seven months of launch, compared to competitors who have been in the market longer [39] - **Transition from Competitors**: 30% of new patients on Yutrepia are transitioning from oral therapies, indicating a successful displacement strategy [10][32] Future Outlook - **Growth Projections**: The company aims to achieve over $1 billion in product sales by 2027, driven by increasing prescriptions and market penetration [32][33] - **New Indications**: Plans to explore additional indications for Yutrepia and L606, including studies in IPF and PH-COPD, with potential market opportunities approaching $20 billion cumulatively [24][25] Legal Considerations - **Litigation Status**: Ongoing litigation with United Therapeutics, with confidence in the arguments presented and anticipation of a ruling soon [34] Summary Liquidia is positioned for significant growth in the biopharmaceutical market, particularly in the inhaled drug delivery segment for pulmonary diseases. With a strong financial performance, a robust pipeline, and strategic market penetration, the company is set to capitalize on the substantial unmet needs in this therapeutic area.

Core Viewpoint - The company, Valiant Biopharma-B (09887), has seen a stock price increase of 3.52% to HKD 55.90 following the announcement of its drug, LBL-024, receiving Fast Track designation from the FDA for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1: Drug Development and Regulatory Approvals - LBL-024, a dual-specific antibody targeting PD-L1 and 4-1BB, has now received three regulatory recognitions, including Fast Track designation from the FDA [1] - The drug is currently undergoing Phase II or registration clinical trials for three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC, showcasing first-in-class (FIC) or best-in-class (BIC) potential [1] - The Chief Medical Officer of the company, Dr. Cai Shengli, emphasized that this milestone reflects the drug's significant clinical potential and market prospects, which will accelerate its global development and market entry [1]

Core Viewpoint - The company, Valiant Bio (维立志博-B), has seen its stock price increase by over 4% following the announcement of its dual-specific antibody, LBL-024, receiving Fast Track designation from the FDA for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1 - Valiant Bio's LBL-024 has now received three regulatory recognitions, including Fast Track designation from the FDA, and is currently in Phase II or registration clinical trials for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC [1] - The Chief Medical Officer of Valiant Bio, Dr. Cai Shengli, emphasized that this latest recognition from an international regulatory authority highlights the significant clinical potential and market prospects of LBL-024 [1] - The milestone is expected to accelerate the global development process of LBL-024, facilitating its market entry and benefiting patients worldwide [1]

Core Viewpoint - The company Valiant Bio-B (09887) has received FDA fast track designation for its dual-specific antibody LBL-024, indicating significant clinical potential and market prospects for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1: Regulatory Approvals - LBL-024 has now received three regulatory recognitions, including fast track designation from the FDA for EP-NEC, and previous breakthrough therapy designation from China's NMPA and orphan drug designation from the FDA [1] - The drug is currently in phase II or registration clinical trials for three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC, showcasing first-in-class (FIC) or best-in-class (BIC) potential [1] Group 2: Market Impact - The recognition from international regulatory authorities highlights the drug's substantial clinical potential and market outlook, which is expected to accelerate its global development process and expedite market entry [1] - The stock price of Valiant Bio-B increased by 4.26% to 56.3 HKD, with a trading volume of 3 million HKD, reflecting positive market sentiment following the announcement [1]

Core Insights - T-cell engagers (TCEs) are a focus in precision immunotherapy, showing rapid market growth and clinical advancements in cancer and autoimmune disease treatments [1][4] Market Overview - The global TCE market is projected to reach $5.6 billion by 2025 and $9.5 billion by 2026, with China's market expected to grow to $300 million and $600 million respectively [1][4] - Since 2024, the TCE sector has seen significant transaction activity, with 28 transactions recorded in 2024 and a total of 179 transactions from 2013 to 2024 [4][5] Clinical Trials - In 2024, there were 175 TCE clinical trials initiated globally, with 115 focused on hematological cancers, representing 65% of the market share [4] - The number of clinical trials for autoimmune diseases is expected to grow significantly, matching the 32 trials for solid tumors initiated in 2024 [4] Industry Definition and Classification - TCEs are a subgroup of immunotherapy that utilize bispecific antibodies to direct T-cells to kill tumor cells, classified into three main types: IgG-like TCEs, Fv-based TCEs, and combination-based TCEs [2][3] Industry Development - The development of TCEs has evolved over 40 years, from the initial concept in 1961 to clinical applications, with significant milestones in 1985 and 2008 marking key advancements [5][6] Competitive Landscape - Over ten TCEs have been approved globally, with a surge in approvals since 2022, particularly in the hematological cancer space [7] - Key companies involved in TCE development include Amgen, Roche, Johnson & Johnson, and several domestic firms in China such as Guangdong Fipeng Pharmaceutical and Aimi Biotechnology [7][8] Future Trends - TCEs are increasingly being explored for various diseases beyond hematological cancers, including autoimmune diseases, and are becoming a significant area of research in the biopharmaceutical sector [8][9]

Recent Events - Company announced on January 12 that it has signed an exclusive licensing agreement with AbbVie for its self-developed PD-1/VEGF bispecific antibody drug RC148, granting AbbVie exclusive rights for development, production, and commercialization outside Greater China. The company will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, as well as double-digit royalties on net sales outside Greater China [1] Product Development and International Collaboration - The recent licensing agreement further validates the company's speed in international expansion, following the external authorization of its core products RC18 and RC28 by 2025. As of January 2026, there are 17 PD-(L)1/VEGF bispecific antibody drugs in clinical trials globally, with several signed BD agreements, showcasing the company's strong R&D capabilities [2] - AbbVie, as an international MNC, has a diverse product pipeline including the first FRα-targeting ADC drug Elahere and others, which will strategically complement RC148 and expand its global reach [2] Clinical Data and Efficacy - At the 2025 ESMO-IO conference, the company disclosed promising data for RC148, showing an objective response rate (ORR) of 61.9% and a disease control rate (DCR) of 100% for monotherapy. For combination therapy, the ORR reached 66.7% and the DCR was 95.2%, indicating initial clinical advantages and manageable safety profiles [3] - Early clinical studies have shown that RC148, when used in combination with antibody-drug conjugates (ADCs), exhibits promising anti-tumor activity, with the company actively advancing related clinical trials [3]

Core Viewpoint - Huaxi Securities maintains an "overweight" rating for Rongchang Biopharmaceutical (09995), highlighting the company's strong independent R&D capabilities, stable sales growth of core products, experienced management team, steady progress in clinical indications, and reasonable domestic and international layout, with optimism regarding the company's commercialization capabilities post-product launch [1] Recent Events - On January 12, the company announced an exclusive licensing agreement with AbbVie for its independently developed PD-1/VEGF bispecific antibody drug RC148, granting AbbVie exclusive rights for development, production, and commercialization outside Greater China. The company will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with double-digit royalties on net sales outside Greater China [1] International Expansion - Following the authorization of core products RC18 and RC28 in 2025, this recent agreement further validates the company's speed in international expansion. As of January 2026, 17 PD-(L)1/VEGF bispecific antibody drugs are in clinical trials globally, with several BD agreements signed, showcasing the company's R&D capabilities. AbbVie, as a partner, has a diverse product line that complements RC148, enhancing its global positioning [2] Clinical Data - At the 2025 ESMO-IO conference, the company disclosed promising data for RC148, showing an objective response rate (ORR) of 61.9% and a disease control rate (DCR) of 100% in monotherapy. In combination therapy, the ORR reached 66.7% and the DCR was 95.2%. The safety profile is manageable, indicating initial clinical advantages. The company is actively advancing related clinical studies, anticipating further clinical potential [3]